BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Columbia Entrepreneurship - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Columbia Entrepreneurship
X-ORIGINAL-URL:https://entrepreneurship.columbia.edu
X-WR-CALDESC:Events for Columbia Entrepreneurship
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20150101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=UTC:20160211T120000
DTEND;TZID=UTC:20160211T140000
DTSTAMP:20260408T002412
CREATED:20160113T201115Z
LAST-MODIFIED:20160217T234126Z
UID:2289-1455192000-1455199200@entrepreneurship.columbia.edu
SUMMARY:Biopharma Perspective on Early Venture Investing and R&D
DESCRIPTION:Marian Nakada Ph.d\,\nVice President Johnson & Johnson Innovation\nShafique Virani\,\nGlobal Head of Neuroscience\, Ophthalmology & Rare Disease\, Roche\nand\nSteven Weinstein\nManaging Partner\, Novartis Venture Fund\nin conversation with\nOrin Herskowitz\, Executive Director Columbia Technology Ventures \n\n\n\n\nFebruary 11\, 2016\n12:00 Noon\nOn the Morningside Campus of Columbia University\nSchapiro CEPSR\, 4th Floor\, Davis Auditorium\n\n\n\n\n\n\n\nRegister Today\n\n\n\n\n\n\n\n\n\nJoin Columbia Technology Ventures for a lively conversation that will touch on the various ways Big Pharma & Biotech are using venture capital investing\, regional innovation centers\, joint ventures\, university research sponsorship\, and IP licensing to source their next blockbuster products (as well as generate equity returns). The panelists will share their perspectives on venture capital investing strategies in biopharma\, how to pitch strategic investors\, the surge in biotech IPOs\, hot research areas within biopharma\, and best practices for establishing R&D partnerships between industry and academia. \nThis event is co-sponsored by the Lang Center for Entrepreneurship\, Columbia Entrepreneurship\, and the Healthcare and Pharmaceutical Management Program at Columbia Business School. \nMarian Nakada\, Vice President\, Venture Investments\, Johnson & Johnson Innovation\, Marian Nakada\, Ph.D\, Vice President\, Venture Investments\, joined Johnson & Johnson Innovation – JJDC\, Inc. (JJDC) in 2013. She is based in Boston\, Mass. and focuses on pharmaceutical investments in East Coast companies that will create options in areas of strategic interest to Johnson & Johnson. Marian previously held roles in Centocor\, Janssen R&D and Janssen Business Development. She has authored 62 peer-reviewed publications and 14 book chapters and reviews. She has a B.A. in Biology from Harvard College and a Ph.D in Pharmacology from the University of Pennsylvania and currently sits on the boards of Navitor Pharmaceuticals and Padlock Therapeutics. \nShafique Virani\, Global Head of Neuroscience\, Ophthalmology & Rare disease (NORD) Partnering\, Roche\nDr. Virani’s responsibilities in this role encompass all partnering activities within Roche’s NORD franchise\, from academic collaborations to licensing and acquisitions. The NORD partnering group has executed several key partnering transactions on behalf of Roche over the past five years\, including collaborations with ReMynd\, Evotec\, Seaside Therapeutics\, PTC Therapeutics\, Inception 3\, Inception 5\, ISIS\, Laval University\, Prothena and acquisition of Trophos. \nDr. Virani joined Roche in 2004 and served various roles within medical affairs\, marketing and business development in the UK\, USA and Switzerland until 2012\, when he transitioned into his current role based in South San Francisco. Dr. Virani trained as a neurosurgeon in Cambridge\, UK and Boston\, Mass. and holds the Fellowship of the Royal College of Surgeons of England. \nSteven Weinstein\, Managing Partner\, Novartis Venture Fund\nSteven D. Weinstein is a Managing Director in Cambridge\, Mass. Steve focuses on both medical device and therapeutic investments for the fund. Prior to joining NVF\, he was a Principal at Prism Venture Partners where he focused on medical devices. Prior to Prism\, Steve was a Principal and Kauffman Fellow with Mid-Atlantic Venture Funds. He started his career as turnaround CEO\, raising angel funds to buy the assets of a defunct distribution business out of bankruptcy and subsequently rebuilding the business. Steve holds an MBA with distinction from the University of Michigan Business School and a B.S. in mechanical engineering from Columbia University’s School of Engineering and Applied Science. He serves on the Partner’s Healthcare Innovation Advisory Board and the University of Michigan Wolverine Venture Fund Advisory Board. Steve serves on the boards of Advanced Animal Diagnostics\, Autonomic Technologies\, Innocrin\, Intersection Medical and Viamet.
URL:https://entrepreneurship.columbia.edu/event/biopharma-perspective-on-early-venture-investing-and-rd/
ATTACH;FMTTYPE=image/png:https://entrepreneurship.columbia.edu/wp-content/uploads/2013/07/tech2.png
END:VEVENT
END:VCALENDAR